Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Randomized Controlled Trial of Anti-CD20 Together with Anti-CD25 and Anti-CD25 Alone in Induction Phase of Kidney Transplant Recipients with Low to Moderate Immunologic Risk
TCTR20200717003Phase 3Unknown
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, basiliximab in kidney allograft rejection, sponsored by Ratchadaphiseksomphot Endowment Fund. Status: unknown.
02
Drugs
rituximabbasiliximab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on TCTR20200717003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200717003.